Daniel B. Soland - 01 Apr 2022 Form 4 Insider Report for IDERA PHARMACEUTICALS, INC.

Reporting relationship: CHIEF OPERATING OFFICER
Issuer ticker: N/A
Reported as of: 01 Apr 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 04 Apr 2022, 17:43:45 UTC
Prior SEC filing: 26 Jan 2022
Next SEC filing: 09 Jun 2022
Source filing: View source filing
Reporting owner signature: /s/ Daniel B. Soland

Key filing fact

Daniel B. Soland filed Form 4 for IDERA PHARMACEUTICALS, INC. on 04 Apr 2022.

Key facts

This page summarizes Daniel B. Soland's Form 4 filing for IDERA PHARMACEUTICALS, INC..
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 04 Apr 2022, 17:43.

Change

Previous filing in this sequence was filed on 26 Jan 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

IDRA transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +41,500
Change %
Price: $0.000000
Shares after: 41,500
Date: 01 Apr 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 41,500
Exercise price: $0.5350
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The stock option award was granted under the Issuer's 2013 Stock Incentive Plan. The stock option will vest and become exercisable in full on January 24, 2026, with 25% vesting on January 24, 2023, and the remainder vesting in twelve equal quarterly installments over the remaining three years, subject to continued service with the Issuer.